HPV has also been linked to head and neck cancers in men. The researchers who did the study found that the vaccine can reduce the risk of getting these cancers by 50%.
Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.
SNMMI Elects Jean-Luc C. Urbain, MD, PhD, FASNC, as President-Elect at 2024 Annual Meeting itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
Four key breakthroughs mean cancer 'won't be a death sentence' dunyanews.tv - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dunyanews.tv Daily Mail and Mail on Sunday newspapers.
Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.